Compounds > 1,10-phenanthroline-platinum(ii)-ethylenediamine
Page last updated: 2024-12-08
1,10-phenanthroline-platinum(ii)-ethylenediamine
Description
You're asking about a compound that's a bit of a mouthful, so let's break it down:
**1,10-Phenanthroline-platinum(II)-ethylenediamine**
* **1,10-Phenanthroline:** This is a heterocyclic organic molecule with a nitrogen-containing structure. It has a strong tendency to bind to metal ions.
* **Platinum(II):** This refers to the platinum atom with a +2 charge.
* **Ethylenediamine:** This is a small organic molecule with two amine groups. It's also a good ligand (a molecule that binds to a metal ion).
**Structure:**
The full compound is a coordination complex. This means the platinum(II) ion is surrounded by ligands. In this case, it's likely that the platinum(II) ion is bound to two molecules of 1,10-phenanthroline and one molecule of ethylenediamine.
**Importance in Research:**
This specific compound, while interesting, might not be particularly well-studied or widely known. However, the components (platinum, 1,10-phenanthroline, and ethylenediamine) are all important in research:
* **Platinum:** Platinum-based complexes are known for their anticancer activity. Cisplatin, a platinum-based drug, is a common chemotherapy agent.
* **1,10-Phenanthroline:** This molecule is used in various applications, including:
* **Luminescence:** It can form luminescent complexes with metal ions, making it useful in analytical chemistry and material science.
* **Catalysis:** It can act as a ligand in catalysts for various reactions.
* **Ethylenediamine:** This is a common ligand in coordination chemistry. It helps to stabilize metal complexes and can influence their reactivity.
**Research Significance:**
The combination of these components might be explored in research for:
* **Developing new anticancer agents:** By varying the ligands around platinum, researchers can explore different properties and potentially enhance the effectiveness of platinum-based chemotherapy.
* **Studying the interaction of platinum complexes with DNA:** Understanding how platinum complexes interact with DNA is crucial to understanding their anticancer activity.
* **Creating new luminescent materials:** The combination of phenanthroline and platinum might lead to the development of novel materials for optical applications.
**Overall:**
While the specific compound you mentioned might not be widely researched, the individual components are essential in various scientific fields, particularly in medicine, chemistry, and materials science. The potential combinations of these components offer researchers avenues to explore new materials and therapies.
1,10-phenanthroline-platinum(II)-ethylenediamine: forms crystalline product with 3'-CMP; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 171377 |
MeSH ID | M0122637 |
Synonyms (6)
Synonym |
1,10-phenanthroline-platinum(ii)-ethylenediamine |
1,10-phenanthrolineethylenediammineplatinum(ii) |
platinum(2+), (1,2-ethanediamine-n,n')(1,10-phenanthroline-n1,n10)-, (sp-4-2)- |
platinum(ii), ethylenediammine(1,10-phenathroline)- |
54831-91-3 |
DTXSID90203326 |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 6 (60.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.96 (24.57) | Research Supply Index | 2.48 (2.92) | Research Growth Index | 4.45 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |